{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Giraldo NA"],"funding":["Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University","Bristol-Myers Squibb","Stand Up To Cancer–Cancer Research Institute Cancer Immunology Translational Cancer Research Grant","Cancer Immunotherapy Trials Network","Melanoma Research Alliance","National Cancer Institute","NCI NIH HHS","National Institutes of Health","Sidney Kimmel Comprehensive Cancer Center"],"pagination":["99"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6167897"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["6(1)"],"pubmed_abstract":["<h4>Background</h4>We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified.<h4>Methods</h4>Pretreatment FFPE tumor specimens (n = 26) were stained for CD8, PD-L1, and PD-1 by immunohistochemistry/immunofluorescence (IHC/IF), and the density and distribution of positive cells was quantified to determine the associations with anti-PD-1 response. Multiplex IF was used to test a separate cohort of MCC archival specimens (n = 16), to identify cell types expressing PD-1.<h4>Results</h4>Tumors from patients who responded to anti-PD-1 showed higher densities of PD-1+ and PD-L1+ cells when compared to non-responders (median cells/mm<sup>2</sup>, 70.7 vs. 6.7"],"journal":["Journal for immunotherapy of cancer"],"pubmed_title":["Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab."],"pmcid":["PMC6167897"],"funding_grant_id":["SU2C-AACR-DT1012","P30 CA006973","IH/NCI Cancer Center Support Grant P30 CA015704","P30 CA015704","UM1 CA154967","T32 CA193145","K24 CA139052","R01 CA142779"],"pubmed_authors":["Anders RA","Cheever M","Nghiem PT","Sunshine JC","Danilova L","Kaunitz GJ","Lipson EJ","Fling S","Berry S","Giraldo NA","Church CD","Succaria F","Taube JM","Lundgren L","Green B","Ogurtsova A","Soni A","Yearley JH","Nguyen P","Xu H","Engle EL","Miller NJ","Ramchurren N","Stein JE","Cuda JD","Cottrell TR","Topalian SL"],"additional_accession":[]},"is_claimable":false,"name":"Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab.","description":"<h4>Background</h4>We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified.<h4>Methods</h4>Pretreatment FFPE tumor specimens (n = 26) were stained for CD8, PD-L1, and PD-1 by immunohistochemistry/immunofluorescence (IHC/IF), and the density and distribution of positive cells was quantified to determine the associations with anti-PD-1 response. Multiplex IF was used to test a separate cohort of MCC archival specimens (n = 16), to identify cell types expressing PD-1.<h4>Results</h4>Tumors from patients who responded to anti-PD-1 showed higher densities of PD-1+ and PD-L1+ cells when compared to non-responders (median cells/mm<sup>2</sup>, 70.7 vs. 6.7","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Oct","modification":"2025-04-22T12:55:08.892Z","creation":"2019-03-26T23:59:42Z"},"accession":"S-EPMC6167897","cross_references":{"pubmed":["30285852"],"doi":["10.1186/s40425-018-0404-0"]}}